## Supplementary Appendix of

# Diagnostic accuracy of three prevailing rapid antigen tests for detection of SARS-CoV-2 infection in the general population: cross sectional study

RP Venekamp and IK Veldhuijzen, KGM Moons, W van den Bijllaardt, SD Pas, EB Lodder, R Molenkamp, Z Igloi, C Wijers, C Oliveira dos Santos, SB Debast, MJ Bruins, K Polad, CRS Nagel-Imming, W Han, JHHM van de Wijgert, S van den Hof, E Schuit.

## Table of contents

**Table S1** Baseline characteristics of the study population included in the PanBio test with2less invasive sampling technique evaluation.

**Table S2** Diagnostic accuracy variables of PanBio-molecular reference standard test3comparison with less invasive sampling. Values are percentages (95% confidence interval)unless stated otherwise.

**Table S3** Diagnostic accuracy variables of additional secondary analyses of three rapid4antigen tests, with different sampling methods. Values are percentages (95% confidence4interval) unless stated otherwise.4

**Table S4** Two-by-two tables used in primary and secondary analysis to determine6diagnostic accuracy parameters of the BD Veritor<sup>TM</sup> System by Becton Dickinson ('BD-Veritor') using routine sampling (OP-N)6

**Table S5** Two-by-two tables used in primary and secondary analysis to determine8diagnostic accuracy parameters of the Roche/SD Biosensor by Roche Diagnostics ('SD-<br/>Biosensor') using routine sampling (NP)8

**Table S6** Two-by-two tables used in primary and secondary analysis to determine10diagnostic accuracy parameters of the Roche/SD Biosensor by Roche Diagnostics ('SD-<br/>Biosensor') using less invasive sampling (OP-N)10

**Table S7** Two-by-two tables used in primary and secondary analysis to determine12diagnostic accuracy parameters of the PanBio by Abbot ('PanBio') using routine sampling(NP)

**Table S8** Two-by-two tables used in primary and secondary analysis to determine14diagnostic accuracy parameters of the PanBio by Abbot ('PanBio') using less invasive14sampling (OP-N)14

Table S9 GISAID data contributors acknowledgement table	16
Supplementary Material 1: short questionnaire (translated from Dutch)	17
<b>Supplementary Material 2:</b> Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures	18

## References

21

Test	PanBio
Method of sampling	Less invasive: OP-N
Inclusion period	1-14 Jun 2021
Sample size	N = 970
Age [years], mean (SD)#	38.4 (14.9)
Sex, female n $(\%)^{\dagger}$	473 (49.1)
Testing indication, n (%)!	
Symptomatic	613 (63.2)
Pre-/asymptomatic close contact of confirmed SARS-CoV-2 infected individual	236 (24.3)
Other	90 (9.3)
Unknown	31 (3.2)
Vaccinated with at least one dose, n(%)@	301 (31.0)
Type of vaccine, n(%) <sup>\$</sup>	
Astra Zeneca	71 (23.6)
Janssen	20 (6.6)
Moderna	23 (7.6)
Pfizer	182 (60.5)
Unknown	6 (2.0)
Number of vaccinations received, n(%) <sup>\$</sup>	
1	238 (79.1)
2	53 (17.6)
Unknown	11 (3.7)
At least one prior SARS-CoV-2 infection, n(%)§	57 (5.9)
Symptoms at time of sampling, n (%) <sup>‡</sup>	664 (69.7)
Symptom onset, n (%)*	
At day of sampling	56 (8.4)
A day before sampling	306 (46.1)
Two days before sampling	172 (25.9)
Three or more days before sampling	139 (20.9)
Unknown	3 (0.5)
Type of symptoms (self-reported), n (%)*#	
Common cold	610 (91.9)
Shortness of breath	82 (12.3)
Fever	92 (13.9)
Coughing	302 (45.5)
Loss of taste or smell	28 (4.2)
Muscle ache	44 (6.6)
Other symptoms	17 (2.6)

**Table S1** Baseline characteristics of the study population included in the PanBio test with less invasive sampling technique evaluation.

OP-N = combined oropharyngeal and nasal sampling; SD=standard deviation.

In the Netherlands, individuals are notified of a close contact by the Dutch public health service test-and-trace program, and/or the Dutch contact tracing mobile phone application (the CoronaMelder app) and/or an individual with a confirmed SARS-CoV-2 infection (index case). # Age was not available from 6 participants.

<sup>†</sup>Sex not available from 6 participants.

<sup>1</sup>Indication for testing was referral for other reason for 90 participants and unknown for 31 participants.

@ COVID-19 vaccination status not available from 17 participants, including 2 with a positive molecular test result.

<sup>\$</sup> percentage calculated as proportion of those vaccinated

<sup>§</sup> Previous SARS-CoV-2 infection information not available from 20 participants.

\$Symptoms not available for 18 participants, including 2 with a positive molecular test result.

\* percentage calculated as proportion of those with symptoms at time of sampling

<sup>#</sup> totals add up to a number higher than the number of individuals with symptoms at the time of sampling because individuals could report more than one symptom. Table S2 Diagnostic accuracy variables of PanBio-molecular reference standard test comparison with less invasive sampling. Values are percentages (95% confidence interval) unless stated otherwise.

Analysis	Sampling	No.	Prevalence* (%)	Sensitivity	Specificity	PPV	NPV
PanBio (Abbott)							
Primary analysis	OP-N	970	3.4	54.5 (36.4 to 71.9)	100.0 (99.6 to 100.0)	100.0 (81.5 to 100.0)	98.4 (97.4 to 99.1)
Secondary (stratified) analysis:							
Infectiousness viral load cut-off	OP-N	970	2.8	66.7 (46.0 to 83.5)	100.0 (99.6 to 100.0)	100.0 (81.5 to 100.0)	99.1 (98.2 to 99.6)
Symptoms present at sampling <sup>‡</sup> :							
Yes	OP-N	664	3.0	65.0 (40.8 to 84.6)	100.0 (99.4 to 100.0)	100.0 (75.3 to 100.0)	98.9 (97.8 to 99.6)
No	OP-N	288	3.8	27.3 (6.0 to 61.0)	100.0 (99.4 to 100.0)	100.0 (75.3 to 100.0)	98.9 (97.8 to 99.6)
Vaccinated (at least 1 vaccination) <sup>@</sup> :							
Yes	OP-N	301	2.0	50.0 (11.8 to 88.2)	100.0 (98.8 to 100.0)	100.0 (29.2 to 100.0)	99.0 (97.1 to 99.8)
No	OP-N	652	3.8	52.0 (31.3 to 72.2)	100.0 (99.4 to 100.0)	100.0 (75.3 to 100.0)	98.1 (96.7 to 99.0)
Previous SARS-CoV-2 infection <sup>§</sup> :							
Yes	OP-N	57	7.0	0.0 (0.0 to 60.2)	100.0 (93.3 to 100.0)	NC1	93.0 (83.0 to 98.1)
No	OP-N	893	2.9	57.7 (36.9 to 76.6)	100.0 (99.6 to 100.0)	100.0 (78.2 to 100.0)	98.7 (97.8 to 99.4)
Sex <sup>†</sup> :							
Female	OP-N	473	3.2	40.0 (16.3 to 67.7)	100 (99.2 to 100)	100 (54.1 to 100)	98.1 (96.4 to 99.1)
Male	OP-N	491	3.7	66.7 (41.0 to 86.7)	100 (99.2 to 100)	100 (73.5 to 100)	98.7 (97.3 to 99.5)
Age [years]#:							
≥16 to ≤40	OP-N	593	4.2	48.0 (27.8 to 68.7)	100 (99.4 to 100)	100 (73.5 to 100)	97.8 (96.2 to 98.8)
>40 to ≤65	OP-N	317	2.5	75.0 (34.9 to 96.8)	100 (98.8 to 100)	100 (54.1 to 100)	99.4 (97.7 to 99.9)
>65	OP-N	54	0.0	NC2	NC2	NC2	NC2
Testing indication <sup>1</sup> :							
symptomatic	OP-N	613	2.6	75.0 (47.6 to 92.7)	100 (99.4 to 100)	100 (73.5 to 100)	99.3 (98.3 to 99.8)
close contact with SARS-CoV-2 infected individual	OP-N	236	5.1	25.0 (5.5 to 57.2)	100 (98.4 to 100)	100 (29.2 to 100)	96.1 (92.8 to 98.2)

PPV=positive predictive value; NPV=negative predictive value; OP-N = combined oropharyngeal and nasal sampling; NC1 = not calculated

because all Ag-RDT results were negative; NC2 = not calculated because all molecular test results were negative.

\*SARS-CoV-2 infection based on molecular test result.

"Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive

viral culture<sup>1</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL.

\*Symptoms not available for 18 participants, including 2 with a positive molecular test result. @ COVID-19 vaccination status not available from 17 participants, including 2 with a positive molecular test result.

<sup>§</sup> Previous SARS-CoV-2 infection information not available from 20 participants.

\* Sex not available from 6 participants.

<sup>#</sup>Age was not available from 6 participants.

<sup>1</sup>Indication for testing was referral for other reason for 90 participants and unknown for 31 participants.

**Table S3** Diagnostic accuracy variables of additional secondary analyses of three rapid antigen tests, with different sampling methods. Values are percentages (95% confidence interval) unless stated otherwise.

Analysis	Sampling	No.	Prevalence*	Sensitivity	Specificity	PPV	NPV
BD-Veritor System (Beck	ton Dickinson),	n (OP-N)	) = 1441				
Vaccinated (at least 1							
vaccination) <sup>@</sup> :							
Yes	OP-N	152	10.5	62.5 (35.4 to 84.8)	100.0 (97.3 to 100.0)	100.0 (69.2 to 100.0)	95.8 (91.0 to 98.4)
No Describer SADS Call 2	OP-N	1255	12.9	69.8 (62.1 to 76.7)	99.8 (99.3 to 100.0)	98.3 (93.9 to 99.8)	95.7 (94.4 to 96.8)
previous SARS-Cov-2							
Ves	OP-N	102	10.8	64.6(30.8  to  89.1)	100 (96.0  to  100)	100 (59 0 to 100)	95 8 (89 6 to 98 8)
No	OP-N	1291	12.7	70.1(62.5  to  77.0)	99.8 (99.4 to 100)	98.3 (94.0 to 99.8)	95.8 (94.5 to 96.9)
Sex <sup>†</sup> :	01 11	12/1	1217	/011 (0210 10 //10)	)))()()))))()))))	, , , , , , , , , , , , , , , , , , ,	<i>y</i> elo ( <i>y</i> lie to <i>y</i> oly)
Female	OP-N	798	12.8	66.7 (56.6 to 75.7)	99.9 (99.2 to 100)	98.6 (92.2 to 100)	95.3 (93.5 to 96.7)
Male	OP-N	637	13.5	70.9 (60.1 to 80.2)	99.8 (99.0 to 100)	98.4 (91.3 to 100)	95.7 (93.6 to 97.2)
Age [years] <sup>#</sup> :							
$\geq 16$ to $\leq 40$	OP-N	747	11.5	70.9 (60.1 to 80.2)	100 (99.4 to 100)	100 (94.1 to 100)	96.4 (94.7 to 97.6)
>40 to ≤65	OP-N	563	15.8	67.4 (56.7 to 77.0)	100 (99.2 to 100)	100 (94.0 to 100)	94.2 (91.8 to 96.1)
>65	OP-N	128	10.2	61.5 (31.6 to 86.1)	98.3 (93.9 to 99.8)	80.0 (44.4 to 97.5)	95.8 (90.4 to 98.6)
Testing indication:	OD M	501	16.0	72.5 ((1.4), 01.0)	00.5 (00.2 ( 00.0)	0(7(005(00))	05.0 (02.5 ( 06.8)
symptomatic	OP-N OP N	501 800	16.0	72.5 (61.4  to  81.9)	99.5 (98.3  to  99.9) 100 (00 5 to 100)	96.7(88.5  to  99.6) 100(04.4 to 100)	95.0 (92.5  to  96.8) 96.1 (04.4  to  97.3)
SARS-CoV-2 infected	OF-IN	800	11.0	08.8 (38.4 10 78.0)	100 (99.5 to 100)	100 (94.4 to 100)	90.1 (94.4 10 97.5)
individual							
marviau							
<b>SD-Biosensor (Roche Diag</b> Vaccinated (at least 1	gnostics), n (NP	) = 1769,	n (OP-N) = 1689	)			
vaccination) <sup>@</sup> :	ND	0.6	10.4	00.0 (55.5 ) 00.7)	100.0 (05.0 - 100.0)	100.0 ((( 1 - 100.0)	00.0 (02.0 )
Yes	NP	96	10.4	90.0 (55.5 to 99.7)	100.0 (95.8 to 100.0)	100.0 (66.4 to 100.0)	98.9 (93.8 to 100.0)
N	OP-N	224	7.6	82.4 (56.6 to 96.2)	100.0 (98.2 to 100.0)	100.0 (76.8 to 100.0)	98.6 (95.9 to 99.7)
No	NP OP N	1659	12.4	73.7(67.1  to  79.5)	99.8 (99.4 to $100.0$ )	98.1 (94.4  to  99.6)	96.4 (95.3  to  97.3) 97.1 (96.0  to  97.0)
Previous SARS-CoV-2	OP-N	1412	10.1	/3.4 (03.4 10 80.3)	99.8 (99.4 to 100.0)	98.1 (95.4 10 99.8)	97.1 (90.0 10 97.9)
infection <sup>§</sup> :							
Yes	NP	187	10.2	68.4 (43.4 to 87.4)	100.0 (97.8 to 100.0)	100.0 (75.3 to 100.0)	96.6 (92.6 to 98.7)
	OP-N	196	5.6	54.5 (23.4 to 83.3)	99.5 (97.0 to 100.0)	85.7 (42.1 to 99.6)	97.4 (93.9 to 99.1)
No	NP	1568	12.5	75.0 (68.3 to 80.9)	99.8 (99.4 to 100.0)	98.0 (94.3 to 99.6)	96.5 (95.5 to 97.4)
	OP-N	1437	10.4	75.8 (68.2 to 82.5)	99.9 (99.6 to 100.0)	99.1 (95.2 to 100.0)	97.3 (96.3 to 98.1)
Sex <sup>†</sup> :							
Female	NP	894	11.3	73.3 (63.5 to 81.6)	99.6 (98.9 to 99.9)	96.1 (89.0 to 99.2)	96.7 (95.2 to 97.8)
Mala	OP-N	856	8.2	68.6 (56.4  to  79.1)	99.9 (99.3 to 100)	98.0 (89.1 to 99.9)	97.3 (95.9  to  98.3)
Male	NP OP N	871	13.1	75.4 (60.5 to 85.0) 70.6 (60.0 to 87.2)	100 (99.5 to 100) 99.7 (99.0 to 100)	100 (95.8  to  100) 97.4 (90.8 to 99.7)	96.4 (94.9 to 97.6) 97.5 (96.1 to 98.5)
Age [years] <sup>#</sup>	01-10	830	11.2	79.0 (09.9 10 87.2)	<i>99.7</i> ( <i>99.0</i> to 100)	97.4 (90.8 to 99.7)	97.5 (90.1 to 98.5)
>16  to  <40	NP	1029	10.4	75.7 (66.5 to 83.5)	99.9 (99.4 to 100)	98.8 (93.4 to 100)	97.3 (96.0 to 98.2)
	OP-N	1037	8.9	69.8 (59.6 to 78.7)	99.8 (99.3 to 100)	97.1 (89.9 to 99.6)	97.1 (95.9 to 98.1)
>40 to ≤65	NP	612	14.1	76.7 (66.4 to 85.2)	99.6 (98.6 to 100)	97.1 (89.9 to 99.6)	96.3 (94.4 to 97.7)
	OP-N	521	11.1	79.3 (66.6 to 88.8)	99.8 (98.8 to 100)	97.9 (88.7 to 99.9)	97.5 (95.6 to 98.7)
>65	NP	124	17.7	59.1 (36.4 to 79.3)	100 (96.4 to 100)	100 (75.3 to 100)	91.9 (85.2 to 96.2)
	OP-N	91	9.9	100 (66.4 to 100)	100 (95.6 to 100)	100 (66.4 to 100)	100 (95.6 to 100)
Testing indication <sup>1</sup> :							
symptomatic	NP	952	13.3	88.2 (81.3 to 93.2)	99.8 (99.1 to 100)	98.2 (93.8 to 99.8)	98.2 (97.1 to 99.0)
1 4 4 41	OP-N	759	12.1	81.5 (72.1 to 88.9)	99.9 (99.2 to 100)	98.7 (92.9 to 100)	97.5 (96.0 to 98.5)
SARS-CoV-2 infected	NP	688	11.5	55.7 (44.1 to 66.9)	99.8 (99.1 to 100)	97.8 (88.2 to 99.9)	94.6 (92.5 to 96.2)
individual							
	OP-N	752	8.0	63.3 (49.9 to 75.4)	99.9 (99.2 to 100)	97.4 (86.5 to 99.9)	96.9 (95.4 to 98.1)
PanBio (Abbott), n (NP) = Vaccinated (at least 1 vaccination) <sup>@</sup> :	970						
Yes	NP	167	7.8	69.2 (38.6 to 90.9)	100.0 (97.6 to 100.0)	100.0 (66.4 to 100.0)	97.5 (93.6 to 99.3)
No	NP	1817	8.5	68.8 (60.9 to 76.0)	99.9 (99.7 to 100.0)	99.1 (94.9 to 100.0)	97.2 (96.3 to 97.9)
Previous SARS-CoV-2 infection <sup>§</sup> :							· · · · · · · · · · · · · · · · · · ·
Yes	NP	134	11.9	62.5 (35.4 to 84.8)	100.0 (96.9 to 100.0)	100.0 (69.2 to 100.0)	95.2 (89.8 to 98.2)
No	NP	1850	8.1	70.0 (62.0 to 77.2)	99.9 (99.7 to 100.0)	99.1 (94.9 to 100.0)	97.4 (96.6 to 98.1)
Sex <sup>†</sup> :						· · · ·)	
Female	NP	1075	7.1	69.7 (58.1 to 79.8)	99.9 (99.4 to 100)	98.1 (90.1 to 100)	97.7 (96.6 to 98.6)

Male	NP	977	9.9	68.0 (57.8 to 77.1)	100 (99.6 to 100)	100 (94.6 to 100)	96.6 (95.2 to 97.7)
Age [years] <sup>#</sup> :							
≥16 to ≤40	NP	1307	7.5	61.2 (50.8 to 70.9)	100 (99.7 to 100)	100 (94.0 to 100)	97.0 (95.8 to 97.8)
>40 to ≤65	NP	635	10.9	79.7 (68.3 to 88.4)	99.8 (99.0 to 100)	98.2 (90.4 to 100)	97.6 (96.0 to 98.7)
>65	NP	112	5.4	66.7 (22.3 to 95.7)	100 (96.6 to 100)	100 (39.8 to 100)	98.1 (93.5 to 99.8)
Testing indication <sup>1</sup> :							
symptomatic	NP	1273	7.5	70.8 (60.7 to 79.7)	99.9 (99.5 to 100)	98.6 (92.2 to 100)	97.7 (96.7 to 98.4)
close contact with	NP	594	9.9	64.4 (50.9 to 76.4)	100 (99.3 to 100)	100 (90.7 to 100)	96.2 (94.3 to 97.6)
SARS-CoV-2 infected							
individual							

NP = deep nasopharyngeal; OP-N = combined oropharyngeal and nasal sampling; PPV=positive predictive value; NPV=negative predictive value.

\*SARS-CoV-2 infection based on molecular test result.

@ COVID-19 vaccination status not available from 34, 14, 53, and 72 participants, including 7, 0, 4, and 7 with a positive molecular test

result, in the BD-Veritor group, SD-Biosensor NP group, SD-Biosensor OP-N group, and PanBio NP group, respectively.

<sup>§</sup> Previous SARS-CoV-2 infection information not available from 48, 14, 56, and 72 participants in the BD-Veritor group, SD-Biosensor NP group, SD-Biosensor OP-N group, and PanBio NP group, respectively. <sup>†</sup>Sex not available from 6, 4, 3, and 4 participants in the BD-Veritor group, SD-Biosensor NP group, SD-Biosensor OP-N group, and PanBio

NP group, respectively.

<sup>#</sup>Age was not available from 3, 4, 4, and 2 participants in the BD-Veritor group, SD-Biosensor NP group, SD-Biosensor OP-N group, and PanBio NP group, respectively.

'Indication for testing was referral for other reason for 73, 92, 93, and 91 participants and unknown for 67, 37, 85, and 98 participants in the BD-Veritor group, SD-Biosensor NP group, SD-Biosensor OP-N group, and PanBio NP group, respectively.

**Table S4** Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the BD Veritor<sup>TM</sup> System by Becton Dickinson ('BD-Veritor') using routine sampling (OP-N)

Analysis	Subgroup				
Primary Secondary (stratified):		Test+ Test- Total	Ref+ 129 59 188	Ref- 2 1251 1253	Total 131 1310 1441
Infectiousness viral load cut-off¶		Test+ Test- Total	Ref+ 125 21 146	Ref- 6 1289 1295	Total 131 1310 1441
Symptoms present at sampling‡:	Yes	Test+ Test- Total	Ref+ 91 29 120	Ref- 1 541 542	Total 92 570 662
	No	Test+ Test- Total	Ref+ 33 26 59	Ref- 1 682 683	Total 34 708 742
Vaccinated (at least 1 vaccination) <sup>@</sup> :	Yes	Test+ Test- Total	Ref+ 10 6 16	Ref- 0 136 136	Total 10 142 152
	No	Test+ Test- Total	Ref+ 113 49 162	Ref- 2 1091 1093	Total 115 1140 1255
Previous SARS-CoV-2 infection <sup>§</sup> :	Yes	Test+ Test- Total	Ref+ 7 4 11	Ref- 0 91 91	Total 7 95 102
	No	Test+ Test- Total	Ref+ 115 49 164	Ref- 2 1125 1127	Total 117 1174 1291
Sex <sup>†</sup> :	Female	Test+ Test- Total	Ref+ 68 34 102	Ref- 1 695 696	Total 69 729 798
	Male	Test+ Test- Total	Ref+ 61 25 86	Ref- 1 550 551	Total 62 575 637
Age [years] <sup>#</sup> :	$\geq 16$ to $\leq 40$	Test+ Test- Total	Ref+ 61 25 86	Ref- 0 661 661	Total 61 686 747
	>40 to ≤65	Test+ Test- Total	Ref+ 60 29 89	Ref- 0 474 474	Total 60 503 563
	>65	Test+ Test- Total	Ref+ 8 5 13	Ref- 2 113 115	Total 10 118 128
Testing indication <sup>1</sup> :	symptomatic	Test+ Test- Total	Ref+ 58 22 80	Ref- 2 419 421	Total 60 441 501

close contact with		Ref+	Ref-	Total
SARS-CoV-2	Test+	64	0	64
infected individual	Test-	29	707	736
	Total	93	707	800

Ref = molecular reference standard test; Test = BD Veritor<sup>TM</sup> System by Becton Dickinson

¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>1</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL

SARS-CoV-2 infection information not available from 48 participants.
 <sup>8</sup> Previous SARS-CoV-2 infection information not available from 48 participants.
 <sup>5</sup> Sex not available from 6 participants.

\_\_\_\_

<sup>#</sup>Age was not available from 7 participants. <sup>1</sup>Indication for testing was referral for other reason for 73 participants and unknown for 67 participants.

**Table S5** Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the Roche/SD Biosensor by Roche Diagnostics ('SD-Biosensor') using routine sampling (NP)

Analysis	Subgroup				
Primary			Ref+	Ref-	Total
		Test+	160	3	163
		Test-	55 215	1551	1606
Secondary (stratified):		1 otal	215	1554	1709
Infectiousness viral load cut-off			Ref+	Ref-	Total
II.		Test+	160	3	163
		Test-	22	1584	1606
		Total	182	1587	1769
Symptoms present at sampling:	Yes		Ref+	Ref-	Total
		Test+	126	2	128
		Test-	25	938	963
		Total	151	940	1091
	No	_	Ref+	Ref-	Total
		Test+	34	1	35
		Test-	29 63	594 595	623 658
		Totai	03	595	038
Vaccinated (at least 1 vaccination) <sup>@</sup> :	Yes		Ref+	Ref-	Total
		Test+	9	0	9
		Test-	1	86	87
		Total	10	86	96
	No		Ref+	Ref-	Total
		Test+	151	3	154
		Test-	54	1451	1505
		Total	205	1454	1659
Previous SARS-CoV-2 infection <sup>§</sup> :	Yes		Ref+	Ref-	Total
		Test+	13	0	13
		Test-	6	168	174
		Total	19	168	187
	No		Ref+	Ref-	Total
		Test+	147	3	150
		Test-	49	1369	1418
		Total	196	1372	1568
Sex <sup>†</sup> :	Female		Ref+	Ref-	Total
		Test+	74	3	77
		Test-	27	790	817
		Total	101	793	894
	Male	_	Ref+	Ref-	Total
		Test+	86	0	86
		Total	28 114	/5/ 757	785 871
		10111			
Age [years] <sup>#</sup> :	$\geq 16$ to $\leq 40$	<b>T</b>	Ref+	Ref-	Total
		I est+	81 26	1 921	82 947
		Total	107	921	1029
	>40 to ≤65	_	Ref+	Ref-	Total
		Test+	66	2	68
		Test-	20	524 526	544 612
		Total	00	520	012
	>65	_	Ref+	Ref-	Total
		Test+	13	0	13
		Test-	9 22	102	111
		i otal	22	102	124
Testing indication':	symptomatic	_	Ref+	Ref-	Total
		Test+	112	2	114
		Test-	15	823	838
		I otal	127	823	952

close contact with		Ref+	Ref-	Total
SARS-CoV-2	Test+	44	1	45
infected individual	Test-	35	608	643
	Total	79	609	688

Ref = molecular reference standard test; Test = Roche/SD Biosensor by Roche Diagnostics ¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>1</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL.

SARS-CoV-2 infection information not available from 14 participants.
 <sup>§</sup> Previous SARS-CoV-2 infection information not available from 14 participants.
 <sup>§</sup> Sex not available from 4 participants.

<sup>#</sup>Age was not available from 13 participants. <sup>1</sup>Indication for testing was referral for other reason for 92 participants and unknown for 37 participants.

**Table S6** Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the Roche/SD Biosensor by Roche Diagnostics ('SD-Biosensor') using less invasive sampling (OP-N)

Analysis	Subgroup				
Primary		_	Ref+	Ref-	Total
		Test+	123	3	126
		Test-	41	1522	1563
Socondary (stratified):		1 otai	104	1525	1089
Infectiousness viral load cut-off			Ref+	Ref-	Total
		Test+	118	8	126
		Test-	23	1540	1563
		Total	141	1548	1689
Symptoms present at sampling*	Vec		Ref+	Ref-	Total
Symptoms present at sampling <sub>4</sub> .	105	Test+	90	2	92
		Test-	24	784	808
		Total	114	786	900
	No		Pof⊥	Dof	Total
	INO	Test+	20	0	20
		Test-	17	689	706
		Total	46	689	735
••••••					
Vaccinated (at least 1 vaccination) <sup>@</sup> :	Yes	<b>T</b> · ·	Ref+	Ref-	Total
		Test+	14	0	14
		Test-	3	207	210
		Total	1/	207	224
	No		Ref+	Ref-	Total
		Test+	105	2	107
		Test-	38	1267	1305
		Total	143	1269	1412
Previous SARS-CoV-2 infection <sup>§</sup> :	Yes		Ref+	Ref-	Total
		Test+	6	1	7
		Test-	5	184	189
		Total	11	185	196
	No		Ref+	Ref-	Total
	110	Test+	113	1	114
		Test-	36	1287	1323
		Total	149	1288	1437
Sex <sup>†</sup> :	Female		Ref+	Ref-	Total
	1 0111410	Test+	48	1	49
		Test-	22	785	807
		Total	70	786	856
	Male		Ref+	Ref-	Total
		Test+	74	2	76
		Test-	19	735	754
		Total	93	737	830
Age [vears] <sup>#</sup> :	>16 to <40		Ref+	Ref-	Total
<u> </u>	_10 10 _10	Test+	67	2	69
		Test-	29	975	1004
		Total	96	977	1073
	>40 to <65		Ref+	Ref-	Total
	> 10 ≤00	Test+	46	1	47
		Test-	12	462	474
		Total	58	463	521
					_
	>65	Tact	Ref+	Ref-	Total
		Test+	9	0 00	9 07
		Total	9	82 82	82 91
m at the state			D.C.	D C	
Testing indication:	symptomatic	Test+	Ref+ 75	Ref-	Total 76
		Test-	17	666	683
		1001-	1/	000	005

close contact with	1	Ref+	Ref-	Total
SARS-CoV-2	Test+	38	1	39
infected individua	l Test-	22	691	713
	Total	60	692	752

Ref = molecular reference standard test; Test = Roche/SD Biosensor by Roche Diagnostics

¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>1</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL.

SARS-CoV-2 infection information not available from 56 participants.
 <sup>§</sup> Previous SARS-CoV-2 infection information not available from 56 participants.
 <sup>§</sup> Sex not available from 3 participants.

<sup>#</sup>Age was not available from 13 participants. <sup>1</sup>Indication for testing was referral for other reason for 93 participants and unknown for 85 participants.

Analysis	Subgroup				
Primary	~ ^		Ref+	Ref-	Total
		Test+	119	1	120
		Test-	54	1882	1936
Secondary (stratified).		Total	173	1883	2056
Infortiousnoss viral load out of als			Ref+	Ref-	Total
infectiousness virai load cut-on		Test+	108	2	110
		Test-	13	1916	1929
		Total	121	1918	2039
Symptoms present at sampling:	Yes		Ref+	Ref-	Total
		Test+	96	1	97
		Test-	37	1336	1373
		Total	133	1337	1470
	No		Ref+	Ref-	Total
	140	Test+	19	0	19
		Test-	15	477	492
		Total	34	477	511
Vaccinated (at least 1 vaccination) <sup>@</sup> :	Yes		Ref+	Ref-	Total
		Test+	9	0	9
		Test-	4	154	158
		Total	13	154	167
	No		Daf	Def	Tatal
	INO	Test+	106	1	10121
		Test-	48	1662	1710
		Total	154	1663	1817
		rotur	10.	1000	1017
Previous SARS-CoV-2 infection <sup>§</sup> :	Yes		Ref+	Ref-	Total
		Test+	10	0	10
		Test-	6	118	124
		Total	16	118	134
	N			D C	T ( 1
	No	Test	105 Kei+	Kei-	1 otal
		Test	105	1600	1744
		Total	150	1700	1850
		Totai	150	1700	1050
Sex <sup>†</sup> :	Female		Ref+	Ref-	Total
		Test+	53	1	54
		Test-	23	998	1021
		Total	76	999	1075
	24.1		D.C.	D C	<b>T</b> (1
	Male	Test	Ref+	Ref-	lotal
		Test+	00 21	0	00
		Total	97	880	911
		Totai	71	000	211
Age [years] #:	≥16 to ≤40		Ref+	Ref-	Total
		Test+	60	0	60
		Test-	38	1209	1247
		Total	98	1209	1307
	10		D.C.	D C	T ( 1
	>40 to ≤65	<b>T</b> · ·	Ket+	Ket-	Total
		Test+	55	1	56 570
		Total	14 60	565 566	519
		TOTAL	09	500	035
	>65		Ref+	Ref-	Total
		Test+	4	0	4
		Test-	2	106	108
		Total	6	106	112
man an an an an a	-			<b>.</b> -	
Testing indication:	symptomatic	<b>m</b> · ·	Ref+	Ref-	Total
		Test+	68	l 1176	69
		Total	28	1176	1204
		rotar	90	11//	12/3

**Table S7** Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the PanBio by Abbot ('PanBio') using routine sampling (NP)

close contact with		Ref+	Ref-	Total
SARS-CoV-2	Test+	38	0	38
infected individual	Test-	21	535	556
	Total	59	535	594

Ref = molecular reference standard test; Test = PanBio by Abbot ¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>1</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL. <sup>§</sup>Viral load unavailable for 17 participants. <sup>‡</sup>Symptoms not available for 75 participants. <sup>@</sup> COVID-19 vaccination status not available from 72 participants. <sup>§</sup> Previous SARS-CoV-2 infection information not available from 72 participants. <sup>†</sup> Sex not available from 4 participants. <sup>#</sup> Age was not available from 17 participants

<sup>#</sup>Age was not available from 17 participants. <sup>1</sup>Indication for testing was referral for other reason for 91 participants and unknown for 98 participants.

**Table S8** Two-by-two tables used in primary and secondary analysis to determine diagnostic accuracy parameters of the PanBio by Abbot ('PanBio') using less invasive sampling (OP-N)

Analysis	Subgroup				
Primary			Ref+	Ref-	Total
-		Test+	18	0	18
		Test-	15	937	952
		Total	33	937	970
Secondary (stratified): Infectiousness viral load cut-off			Ref+	Ref-	Total
		Test+	18	0	18
		Test-	9	943	952
		Total	27	943	970
Symptoms present at	Yes		Ref+	Ref-	Total
sampling:		Test+	13	0	13
		Test-	7	644	651
		Total	20	644	664
	No	<b>T</b> (1)	Ref+	Ref-	Total
		Test+	3	0	3
		Test-	8	277	285
		Total	11	277	288
Vaccinated (at least 1 vaccination) <sup>@</sup> :	Yes		Ref+	Ref-	Total
,		Test+	3	0	3
		Test-	3	295	298
		Total	6	295	301
	No		Ref+	Ref-	Total
	110	Test+	13	0	13
		Test-	12	627	639
		Total	25	627	652
			D (		TT + 1
infection <sup>§</sup> :	Yes	<b>T</b>	Ret+	Ret-	Total
		Test+	0	0	0
		Test-	4	53	57
		Total	4	53	57
	No		Ref+	Ref-	Total
		Test+	15	0	15
		Test-	11	867	878
		Total	26	867	893
Sev†·	Female		Ref+	Ref-	Total
Sex :	1 ciliare	Test+	6	0	6
		Test-	9	458	467
		Total	15	458	473
	Male		Ref+	Ref-	Total
		Test+	12	0	12
		Test-	6	473	479
		Total	18	473	491
Age [years] <sup>#</sup> :	>16 to <40		Ref+	Ref-	Total
		Test+	12	0	12
		Test-	13	568	581
		Total	25	568	593
	. 10		Def	D - C	T. ( 1
	>40 to ≤65	T - 11	Kei+	Ke1-	i otai
		T est+	0	0	0
		1 est- Total	2 8	309	311 317
				5.5	
	>65	Tect	Ref+	Ref-	Total
		Test+	0	0	0
		Total	0	0 0	04 0
		10141	v	v	U U
Testing indication <sup>1</sup> :	symptomatic		Ref+	Ref-	Total

	Test+	12	0	12
	Test-	4	597	601
	Total	16	597	6013
close contact		Ref+	Ref-	Total
with	Test+	3	0	3
SARS-CoV-2	Test-	9	224	233
infected	Total	12	224	236
individual				

Ref = molecular reference standard test; Test = PanBio by Abbot ¶Viral load cut-off for infectiousness, defined as viral load above which 95% of people with a positive RT-PCR test result had a positive viral culture<sup>1</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL.

Viral culture<sup>2</sup> was 5.2 log10 SARS-CoV-2 E-gene copies/mL.
<sup>‡</sup>Symptoms not available for 18 participants.
<sup>@</sup> COVID-19 vaccination status not available from 17 participants.
<sup>§</sup> Previous SARS-CoV-2 infection information not available from 20 participants.
<sup>†</sup> Sex not available from 6 participants.
<sup>#</sup> Age was not available from 10 participants.
<sup>!</sup> Indication for testing was referral for other reason for 90 participants and unknown for 31 participants.

## Table S9 GISAID data contributors acknowledgement table

We gratefully acknowledge the following Authors from the Originating laboratories responsible for obtaining the specimens and the Submitting laboratories where genetic sequence data were generated and shared via the GISAID Initiative, on which this research is based.

AccessionID	Originating laboratory	Submitting laboratory	Authors
EPI_ISL_5855699	Dutch COVID-19 response team	Erasmus Medical Center	Bas Oude Munnink, Reina Sikkema, David
			Nieuwenhuijse, Irina Chestakova, Anne van der Linden,
			Marjan Boter, Emmanuelle Munger, Corine
			GeurtsvanKessel, Annemiek van der Eijk, Richard
			Molenkamp, Marion Koopmans, on behalf of the Dutch
			national COVID-19 response team.
EPI_ISL_2731321,	Microvida	Microvida	Suzan D. Pas, Jaco J. Verweij, Joep J. J. M. Stohr.
EPI_ISL_2731323,			
EPI_ISL_2731327,			
EPI_ISL_2731348			
EPI_ISL_2925600-05,			
EPI_ISL_2955624-26,			
EPI_ISL_5051430-33,			
EPI_ISL_5825426-27,			
EPI_ISL_5846285-86,			
EPI ISL 6182027.			

All submitters of data may be contacted directly via https://www.gisaid.org

## Supplementary Material 1 Short questionnaire (translated from Dutch)

- 1. What is the reason for testing?
  - Multiple answers possible
    - I have (had) Covid-19 like symptoms
    - I am a close contact of a SARS-CoV-2 infected person
    - Date of last contact: \_\_\_\_\_- (day month)
    - I was notified because of:
    - The infected person is a household member  $\Box$  yes /  $\Box$  no
    - Received notification by CoronaMelder app (English: Corona notification app)  $\square$  yes /  $\square$  no
    - Received notification by public health service (by phone or letter)  $\Box$  yes /  $\Box$  no
    - Received notification by SARS-CoV-2 infected person □ yes / □ no
    - Other, .....

GP recommended a SARS-CoV-2 test Travelled to a high-pandemic country

- None of the above, but.....
- 2. Did you receive a Covid-19 vaccination
  - 🗌 No
  - Yes

If yes, which vaccine did you receive?  $\Box$  Pfizer  $\Box$  Moderna  $\Box$  AstraZeneca  $\Box$  Janssen  $\Box$  Unknown Which number of vaccinations did you receive?  $\Box$  One  $\Box$  Two

3. Did you have had a positive SARS-CoV-2 test previously? If yes, how long ago?  $\Box$  No  $\Box < 2$  months  $\Box = 2-6$  months  $\Box = 6-12$  months  $\Box > 12$  months

- 4. At this moment, do you have any COVID-19 like symptoms?
  - □ No END OF QUESTIONNAIRE
     □ Yes
- 5. What COVID-19 like symptoms do you currently have?

Multiple answers possible

- Common cold
- Shortness of breath
- Fever
- Coughing
- Loss of taste or smell
- Muscle ache
- I have other symptoms
- 6. What was the moment you first experienced these symptoms?
  - 🗌 Today
  - Yesterday
  - Two days ago
  - Three or more days ago

## **Supplementary Material 2** Specimen collection, SARS-CoV-2 diagnostic testing, and SARS-CoV-2 virus culture procedures

#### Specimen collection and SARS-CoV-2 diagnostic testing procedures

West Brabant region, Microvida laboratories at Amphia hospital in Breda and Roosendaal: BD-Veritor

At this location, the BD Veritor<sup>TM</sup> by Becton Dickinson Ag-RDT ('BD-Veritor') was used for routine SARS-CoV-2 testing extended with additional RT-PCR testing as reference standard test. Two swabs were taken per person at the Public Health Service test site in the Amphia hospital in Breda. For the RT-PCR, a superficial combined oropharyngeal and nasal (OP-N) swab (about 2.5 cm deep from the edge of the nostril) was taken, placed in universal transport media (HiViralTM) with MagnaPure LC lysis- and binding buffer (Roche Diagnostics, The Netherlands), and transported to the Microvida laboratory in Roosendaal. RT-PCR was performed using the cobas ® SARS-CoV-2 test on the cobas ® 8800 platform (Roche Diagnostics International, Rotkreuz, Switzerland). Ct values for the SARS-CoV-2 E-gene were converted to viral load (genome copies/ml) based on an in-house established standard curve. The assay was used in accordance with the manufacturer's instructions; amplification curves and cycle threshold values were interpreted using the manufacturer's interpretation algorithms, which complied with the European in-vitro diagnostic devices directive. For Ag-RDT testing, the second combined OP-N swab was stored in a sterile dry tube immediately after collection and taken to the on-site Microvida laboratory in the Amphia hospital in Breda. A trained laboratory technician performed the Ag-RDT in accordance with the manufacturer's operating procedure within one hour after the specimen was obtained. The system is intended to be used with a digital reader although validated for visual reading.<sup>2</sup> In this study, visual readout was performed independently by two persons. In case of discrepancies, the result from the digital reader was used.

#### Rotterdam city region, laboratory Erasmus MC: SD-Biosensor

At this location, the Roche/SD Biosensor by Roche Diagnostics ('SD-Biosensor') Ag-RDT was used for routine SARS-CoV-2 testing extended with additional RT-PCR testing as the reference standard test. Two swabs were taken per person at the two Public Health service test sites in Rotterdam-Rijnmond region (Rotterdam Airport and Ahoy). For RT-PCR, a deep combined OP-N swab (>5 cm deep from the edge of the nostril) was taken, placed directly in universal transport media (HiViralTM) and transported to the Erasmus MC Viroscience diagnostic laboratory. Routine RT-PCR testing was performed in virus transport medium using the cobas ® SARS-CoV-2 test on the cobas 6800® platform (Roche Diagnostics International, Rotkreuz, Switzerland). The assay was used in accordance with the manufacturer's instructions; amplification curves and cycle threshold values were interpreted using the manufacturer's interpretation algorithms, which complied with the European in-vitro diagnostic devices directive. The second swab was used for on-site Ag-RDT testing, and procedures differed slightly for the two different sampling methods that were evaluated.

#### SD-Biosensor Ag-RDT evaluation using routine sampling

A nasopharyngeal (NP) swab (>5 cm deep from the edge of the nostril) was taken using the swab included in the SD-Biosensor Ag-RDT kit (REF No. 9901-NCOV-01G; LOT No QCO3020079/Sub:A-2). The test was carried out immediately on-site at the two Public Health Service test sites in Rotterdam following manufacturer's instructions. Interpretation and recording of test results was performed independently by two persons according to the manufacturer's instructions.

#### SD-Biosensor Ag-RDT evaluation using less invasive sampling

A superficial combined OP-N swab (about 2.5 cm from the edge of the nostril) was taken using the swab included in the SD-Biosensor Ag-RDT kit (REF No. 9901-NCOV-01G; LOT No QCO3020079/Sub:A-2). The test was carried out immediately on-site at the two Public Health Service test sites in Rotterdam following manufacturer's instructions. Interpretation and recording of test results was performed independently by two persons according to the manufacturer's instructions.

#### Zwolle region, Laboratory of Medical Microbiology and Infectious Diseases, Isala Hospital: PanBio

The standard method for SARS-CoV-2 testing in Isala Hospital is by transcription mediated (TMA) amplification on the Hologic Panther system (AptimaTM SARS-CoV2 assay). It was carried out as usual, in parallel with the PanBio Ag-RDT. TMA positive samples were further analysed by RT-PCR to obtain Ct values for viral load calculation. These samples were stored at 4-8 degrees Celsius until processed for RT-PCR with a maximum of 24 hours during the week and 72 hours in the weekend. In case of discrepant results (TMA-positive, RT-PCR negative), the RT-PCR was repeated once due to possible sampling error. If there was still discrepancy between results, a Ct value of 40 was assigned for subsequent analysis (8/173 (4.6%) and 1/33 (3.0%) participants with a positive reference standard test in the routine sampling and less invasive sampling periods, respectively).

Two swabs were taken per person at the Public Health service test site in Zwolle. For TMA/RT-PCR, a deep combined OP-N swab (>5 cm deep from the edge of the nostril) was taken, placed in 1x Tris-EDTA buffer (Sigma-

Aldrich), and transported to the Isala Hospital Laboratory for Medical Microbiology and Infectious Diseases for analysis in Zwolle. The in-house RT-PCR was performed based on Corman et al.<sup>3</sup> RNA extraction was performed on the KingFisher Flex System (ThermoFisher) using the MagMAX Viral/Pathogen Nucleic Acid Isolation Kit with the manufacturer protocol MVP\_2Wash\_200\_Flex\_SARS-COV2 (ThermoFisher). RT-PCR and detection was performed with the TaqMan Fast Virus 1-Step Mastermix (ThermoFisher) on the ABI7500 platform (Applied Biosystems). This RT-PCR has one target: the SARS-CoV-2 E-gene. The second swab was used for on-site Ag-RDT testing, and procedures differed slightly for the two different sampling methods that were evaluated.

#### PanBio Ag-RDT evaluation using routine sampling

A deep NP swab (>5 cm deep from the edge of the nostril) was taken and tested by PanBio Ag-RDT at thePublic Health Service test site in Zwolle. The collected swab was transferred into supplied extraction tubes. A trained laboratory technician performed the Ag-RDT in accordance with the manufacturer's operating procedure within 2 hours after the specimen was obtained. Readout was performed independently by two persons.

#### PanBio Ag-RDT evaluation using less invasive sampling

A superficial combined OP-N swab (about 2.5 cm from the edge of the nostril) was tested by the PanBio Ag-RDT at the Public Health Service test site in Zwolle. The collected swab was transferred into supplied extraction tubes. A trained laboratory technician performed the Ag-RDT in accordance with the manufacturer's operating procedure within 2 hours after the specimen was obtained. Readout was performed independently by two persons.'

#### Viral load calculation

We used a viral load cut-off as a proxy of infectiousness of  $\geq$ 5.2 log10 SARS-CoV-2 E-gene copies/mL, which was the viral load cut-off above which 95% of people with a positive molecular test had a positive virus culture in a recent previous study by our group.<sup>1</sup> For that study, the Erasmus MC viroscience laboratory created a standard curve by testing dilutions of a specific quantified E-gene transcript (primary standard) available from the European Virus Archive (EVAg<sup>4</sup>) with the RT-PCR described by Corman et al.<sup>3</sup> The relation between Ct value and number of E-gene copies/ml was determined by linear regression analysis. Based on this calibration curve a secondary standard derived from cell-cultured virus was prepared and quantified. Serial dilutions of this secondary standard were tested by RT-PCR to prepare a secondary standard curve by linear regression.

In the previous study, we determined whether the cobas PCR platform at Microvida laboratory provided comparable data to the cobas PCR platform at Erasmus MC laboratory by having both laboratories test the same SARS-CoV-2 viral load panel obtained from the National Public Health Institute (RIVM). The Ct values generated in the two laboratories corresponded well. In the current study, a third central laboratory (Isala Hospital in Zwolle) participated. This hospital laboratory used the same medium and reagent volumes as the Erasmus MC laboratory. The Erasmus MC laboratory provided a new serial dilution of a virus culture-derived standard provided to the Isala Hospital laboratory, which they tested by RT-PCR in triplicate. Ct values generated by the Isala Hospital laboratory matched the expected Ct values for that standard based on the Ct value obtained by the Erasmus MC laboratory.

Given the above, we concluded that the same formula to convert Ct values into viral loads (copies/ml) could be used for the Zwolle and Rotterdam laboratories This formula was  $62.5 * e^{\frac{43.1-Ct}{1.607}}$ . The Microvida laboratory used lower medium/reagent volumes per swab (1.8 ml compared to 6 ml in the other two laboratories; a factor  $3\frac{1}{3}$ ) and that conversion formula therefore was  $62.5 * e^{\frac{43.1-Ct}{1.607}} / 3\frac{1}{3}$ .

#### Whole genome sequencing (WGS)

In discordant cases (Ag-RDT negative and RT-PCR positive cases) with viral loads above the infectiousness cutoff ( $\geq$ 5.2 log10 SARS-CoV-2 E gene copies/mL) whole genome sequencing (WGS) of the primary clinical specimen was performed by Microvida laboratory to determine the SARS-CoV-2 variant. In short, total nucleic acids were extracted using the QIAsymphony DSP virus pathogen midi kit and pathogen complex 400 protocol of the QIAsymphony Sample Processing system (Qiagen, Germany), with an input volume of 400 µL and output volume of 110 µL.Confirmation SARS-CoV-2 viral load was performed<sup>5</sup> with only samples with Ct value <32 selected for further WGS. cDNA was synthesized using LunaScript® RT SuperMix Kit (New Engeland Biolabs, USA) and library preparation was performed using EasySeq<sup>TM</sup> RC-PCR SARS-CoV-2 Whole Genome Sequencing kit (Nimagen, The Netherlands) according to manufacturer's instructions. Subsequent next generation sequencing (NGS) of 2x150cycles paired end reads was performed on a Miseq (Illumina, The Netherlands) using MiSeq Reagent Micro Kit v2 according to manufacturer's instructions. Data analyses was performed with an inhouse workflow using CLCbio Genomic Workbench v21 (Qiagen, Germany), including (a.o.) read-trimming, NC\_045512.2 (NCBI genbank) reference based assembly, local re-alignment and variant detection algorithms. The consensus genome was extracted and positions with a coverage less than 10 reads were replaced with N. The sequences were manually curated. Genomes with >70% genome coverage were included for lineage assignment using Pangolin (https://pangolin.cog-uk.io/).<sup>6</sup> All genomes with 100% N-gen coverage were used for N-gen mutation analysis using CLCBio Genomic workbench v21 and Nextclade Web 1.7.1 (https://clades.nextstrain.org/).<sup>7</sup> Genomes with >90% genome coverage were uploaded to GISAID (https://www.gisaid.org/).<sup>8</sup> Mutations in the N-gene with a prevalence within their lineage of <10% (according to the mutation tracker tool of https://www.outbreak.info) were reported.<sup>9</sup>

## References

1. Schuit E, Veldhuijzen IK, Venekamp RP, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. BMJ. 2021; 374:n1676. doi: 10.1136/bmj.n1676.

2. Van der Moeren N, Zwart VF, Lodder EB, et al. Evaluation of the test accuracy of a SARS-CoV-2 rapid antigen test in symptomatic community dwelling individuals in the Netherlands. PLoS One 2021;16(5):e0250886. doi: 10.1371/journal.pone.0250886.

3. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* 2020;25(3) doi: 10.2807/1560-7917.ES.2020.25.3.2000045.

4. Archive EV. Wuhan coronavirus 2019 E gene control 2020. Available from: https://www.european-virus-archive.com/nucleic-acid/wuhan-coronavirus-2019-e-gene-control accessed June 8 2021.

5. Sikkema RS, Pas SD, Nieuwenhuijse DF, et al. COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study. Lancet Infect Dis. 2020;20(11):1273-80. doi: 10.1016/S1473-3099(20)30527-2.

6. O'Toole A, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. 2021;7(2):veab064. doi: 10.1093/ve/veab064.

7. Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121-3. doi: 10.1093/bioinformatics/bty407.

8. Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID's innovative contribution to global health. Glob Chall. 2017;1(1):33-46. doi: 10.1002/gch2.1018.

9. Mullen L, Tsueng G, Latif AA, et al. Center for Viral Systems Biology outbreak.info; 2020. Available from: https://outbreak.info/.